Resverlogix Corp. (RVX.TO)
| Previous Close | 0.0650 |
| Open | 0.0700 |
| Bid | 0.0600 x 0 |
| Ask | 0.0650 x 0 |
| Day's Range | 0.0650 - 0.0650 |
| 52 Week Range | 0.0400 - 0.1000 |
| Volume | |
| Avg. Volume | 88,134 |
| Market Cap | 18.003M |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | Nov 07, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileNumerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure hazard among patients taking next-generation glucose lowering drugs Calgary, Alberta--(Newsfile Corp. - September 3, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or "the Company") today announced its presentation at the European Society of Cardiology ("ESC") Congress 2024 in London, UK
NewsfileResverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes ForVotes WithheldPercent ForPercent WithheldDonald J. McCaffrey13
- Baystreet
Stocks in play: Resverlogix Corp.
Has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 ...
